The PSG Executive Committee oversees all the PSG study steering committees, the Scientific Review Committee, the Mentoring Committee, the Nominating Committee, the Credentials Committee, the Publications Committee, the Standards Committee, the Study Budget Committee, and the Symposia Committee. (Click here to view/download the PSG Standing Committee Members list.) The Executive Committee is also responsible for overseeing the PSG working groups (Atypical Parkinsonian Disorders, Cognitive/Psychiatric (Behavior), Biomarkers, Genetics and Environmental Risk, Health/Care Outcomes and Disparities, Other Non-Motor Features of PD, Functional Neurosurgical and Motor Features of PD) that are responsible for developing new PSG projects. PSG members interested in joining a working group may contact the Chair of that group.
Dr. Schwarzschild is a Professor of Neurology at Harvard Medical School and Attending Neurologist at Massachusetts General Hospital. After Parkinson's disease fellowship training at MGH he developed a translational research program focusing on the role of purines — adenosine, caffeine and urate — among environmental and genetic influences in animal models and clinical studies of PD. He has developed and led phase 2/3 clinical trials toward disease-modifying therapy for people with Parkinson’s. At MGH he works with Parkinson's patients and their families in a weekly movement disorders clinic.
Hubert H. Fernandez, MD, is Professor of Neurology at the Cleveland Clinic Lerner College of Medicine, Case Western Reserve University; Chair/Director of the Center for Neurological Restoration at Cleveland Clinic in Cleveland, Ohio. He is the holder of the James and Constance Brown Family Endowed Chair in Movement Disorders. He received both his BS in Biology and MD degree from the Philippines. He completed his internship in Internal Medicine at University of Pennsylvania/Pennsylvania Hospital in Philadelphia, Pennsylvania; his residency in Neurology at Boston University Medical Center in Boston, Massachusetts; and his fellowship in Movement Disorders at Brown University in Rhode Island.
Dr Fernandez is an internationally recognized expert in movement disorders who has been voted one of the Best Doctors in America by his peers. After completing his medical training, he joined the faculty of Brown University School of Medicine as Assistant Professor in the Department of Clinical Neurosciences. In 2003, Dr Fernandez relocated to the University of Florida, where he eventually became Director of the Clinical Research Unit for Neurological and Psychiatric Disorders, Vice Chair of Academic Affairs, and Professor of Neurology prior to joining Cleveland Clinic. An active and productive researcher, he has led or participated in over 150 clinical trials and has published his findings in over 300 articles on Parkinson disease, DBS, behavioral and non-motor features of PD, cervical dystonia, blepharospasm, and other movement disorders. He has written a dozen books and has published 50 book chapters. He is currently the Co-Editor-In-Chief of Parkinsonism and Related Disorders, and has served on the editorial board of Movement Disorders and several other peer-reviewed journals.
Dr Fernandez is a fellow of the American Academy of Neurology and the American Neurological Association. He is currently elected for his second term as the Co-Chair of the Parkinson Study and Secretary of the International Association for Parkinsonism and Related Disorders, He served his third term as Co-Medical Editor of the Movement Disorders Society Website, which received the Standard of Excellence Award twice by the Web Marketing Association during his tenure. He has been a Councilor for the AAN Movement Disorders Section, Sectretary of the MDS Pan-American Section, Executive Committee Member of the Parkinson Study Group and Dystonia Study Group and served as the President of the Florida Society of Neurology and World Neurology Foundation. He was awarded the Most Outstanding Alumnus by his medical school in 2008, and the Presidential Distinguished Service Award by the Movement Disorders Society at the 16th International Congress for Parkinson’s Disease and Movement Disorders in Dublin, Ireland in 2012.
Ms Casaceli has directed the Clinical Trials Coordination Center (CTCC) for over 10 years with more than 25 years experience in the operational conduct of an academic research organization. She has overseen the conduct and compliance of clinical trials that have led to the FDA approve of seven compounds. She has served as the Administrative PI for 8+ studies including NIH funded SURE-PD3, Michael J. Fox Nilo-PD and FoxBioNet, and PDGENE with the Parkinson Foundation. She holds a BS in Biochemistry, MBA in Computer/Information Systems & Accounting, and a Leadership Coaching Certficiate.
Dr Marie-Hélène Saint-Hilaire is the Medical Director of the Parkinson’s Disease and Movement Disorders Center at Boston University and Director of the American Parkinson Disease Association Center for Advanced Research at Boston University Medical Campus. She did her medical school at the Universit de Montréal, and her residency at the Montreal Neurological Institute. Dr Saint-Hilaire has done her movement disorder fellowship at the Hôpital de La Salpêtrière in Paris and at Columbia Presbyterian Hospital in New York. She has been a member of the Parkinson Study Group since 1997 and has been the site PI for several PSG clinical research trials. In addition, she has participated in over 100 clinical research studies evaluating new medications, biomarker observational studies, genetic studies, surgical studies, and studies that address self-management rehabilitation and care. She has also been a member of the PSG Scientific Review Committee. As a member of the Executive Committee, she shares her experience with developing and sustaining a clinical trial program highlighting the important synergy that must exist with all members of the research team. This includes understanding the invaluable role of study coordinators, and the need to actively develop new faculty as investigators at clinical sites. It is also essential that research subjects are well cared for and that a center has strong connections to the community they serve.
Karen is the Sr. Clinical Research Associate at Northwestern University, Parkinson’s Disease & Movement Disorders Center (NUMDC) that is recognized by the Parkinson’s Foundation, Huntington’s disease and Wilson’s Foundations as Centers of Excellence.
Karen has been in the clinical research arena her entire career and has managed, coordinated, and monitored many clinical trials in both Academia and Industry. She serves on several research committees with Northwestern Medicine, as well as outside organizations, providing education, training, and mentoring. Karen’s interest is in providing education and resources for clinical research staff and faculty to help ensure that we provide very valuable and reliable data to our Sponsors. She was also involved with the development of the Chicago Movement Coalition. The Chicago Movement Coalition (CMC) is an alliance of community and academic partners that was established in 2019 to be a resource and advocate for members of the Chicagoland community who are underrepresented in the area of Parkinson’s disease care.
The main goal of the CMC is to empower community members by developing and sustaining educational initiatives about Parkinson’s disease care and research opportunities.
Dr. Macklin is an Assistant in Biostatistics at Massachusetts General Hospital and an Instructor in the Department of Medicine at Harvard Medical School. His research interests focus on neurodegenerative and neurodevelopmental diseases with an emphasis on clinical trial design.
He is an Executive Committee member of the Parkinson Study Group and an academic advisor for the Critical Path for Parkinson's Consortium. He was an organizing member and the lead biostatistician for the Airlie House Clinical Trials Guidelines for ALS research. He is a lead biostatistician for the Healey ALS Center Platform trial, for the phase 3 SURE-PD3 trial in Parkinson disease, and for the Autism Treatment Network. In addition to his work in neurology, he has a long and ongoing interest in evaluation of complementary and alternative medicine, serving as PI or statistician for trials of acupuncture, Tai Chi, and mind-body practices.
Joel S Perlmutter is Head of Movement Disorders and the Elliot Stein Family Professor of Neurology and Professor of Radiology, Neuroscience, Physical Therapy, and Occupational Therapy as well as Director of the American Parkinson Disease Association Advanced Research Center for Parkinson Disease and Director of the Huntington Disease Center of Excellence at Washington University in St. Louis.
Dr. Racette is the Robert Allan Finke Professor and Executive Vice Chairman of Neurology at Washington University School of Medicine in St. Louis and an Honorary Professor of Public Health at the University of the Witwatersrand in Johannesburg, South Africa. Currently, he chairs the PSG mentoring committee. He is a graduate of Princeton University, Northwestern University School of Medicine, and completed his neurology residency and fellowship in movement disorders at Washington University School of Medicine. His research focuses on manganese neurotoxicity and environmental risk factors for Parkinson disease. His research is supported by National Institutes of Health, Michael J. Fox Foundation, U.S. Department of Defense, American Parkinson Disease Association, and Cure Alzheimer Foundation. He has led global health research projects for over a decade in South Africa and Finland. His work in South Africa focuses on occupational and environmental manganese with an emphasis on vulnerable populations. He has served as a peer reviewer and advisor for numerous medical journals and international regulatory agencies. He has received numerous awards and has authored over 160 peer reviewed publications.
Andrew Siderowf, MD MS is the Hurtig-Stern Professor of Neurology and the Chief of the Movement Disorders Division in the Penn Perelman School of Medicine Department of Neurology. He received his MD from Duke University, completed residency training at the Hospital of the University of Pennsylvania and fellowship training in Movement Disorders and Experimental Therapeutics at the University of Rochester (under Ira Shoulson, MD). His research addresses the organization and conduct of clinical trials, particularly the use of biomarkers as outcome measures
Dr. Simuni graduated with her medical degree from Leningrad Medical School and completed an internship in medicine in Leningrad, Russia. Dr. Simuni joined the faculty of the Northwestern University Feinberg School of Medicine in 2000 to build and lead a multidisciplinary movement disorders center that is recognized by the Parkinson’s Foundation, Huntington Disease Society of America and Wilson’s Foundation as a Center of Excellence and serves as a training model in the region. She is the lead investigator of a number of clinical trials on experimental pharmacology, non-motor manifestations, and pharmacological management of PD. She serves on a number of Steering Committees for the PD national clinical trials, several committees of the Parkinson Study Group and the Parkinson Foundation. She is the Site PI and serve on the Steering Committee for the largest PD biomarker initiative funded by the MJFF (PPMI study). Dr. Simuni is the site PI for the Network for Excellence in Neuroscience Clinical Trials (NEXT) Northwestern Clinical Site (U10). Dr. Simuni is an active member of the American Academy of Neurology, American Neurological Association, the Movement Disorders Society as well as the Parkinson’s Study Group.